Anhui BBCA Pharmaceuticals

Li Rongjie, the founder and president of BBCA Group (Fengyuan Group), sits at the top of the decision-making structure. The firm does not operate with an external investment committee; decisions flow through the group's senior leadership. As a corporate investor, the investment process is integrated with the parent company's strategic planning rather than run by a dedicated fund manager.

Anhui BBCA Pharmaceuticals functions as a corporate investment vehicle under Anhui BBCA Group, also known as Fengyuan Group. BBCA Biochemical, a sister entity, manufactures biochemical products such as citric acid and amino acids. In 2012, COFCO Corporation acquired a controlling stake in BBCA Biochemical from the group (per corporate filings, 2012), but BBCA Pharmaceuticals remained under the original parent structure.

The firm operates as a corporate investor deploying its own balance sheet, not as a limited partner in third-party funds. Its investment activity serves the parent group's industrial strategy — primarily direct investments in pharmaceutical manufacturing, technology, and infrastructure that align with existing production capacity.

Senior management participates in the association's Bio-pharmaceutical Development Strategy Committee, which provides direct exposure to industry policy discussions and regulatory developments. This connection is standard operating structure for major Chinese pharmaceutical conglomerates navigating a sector where state policy heavily shapes market access, pricing, and manufacturing standards.

The firm maintains a headquarters and R&D center in Hefei's Baohe Industrial Park while manufacturing operations sit in Bengbu. This split maps directly onto the firm's investment priorities: Hefei supports technology scouting and corporate development, while Bengbu represents the production base that investment activity seeks to expand or strengthen through capacity-driven capital deployment.